Document text
Principal Investigator: Pamela Susan Douglas
Organization: MASSACHUSETTS GENERAL HOSPITAL
Fiscal Year: 2021
Award: $1,210,912
Funding agency: National Heart Lung and Blood Institute
Project Summary
In response to NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements
and revision Supplements on Coronavirus Disease 2019 (COVID-19), and PA-18-591 Administrative
Supplements for existing NIH Grants and Cooperative Agreements, the enclosed administrative supplement,
leveraging parent grant U01 HL123336, is submitted for consideration. Understanding COVID-related CV
complications in at-risk populations represents an urgent national priority. Retrospective case series have
shown that among patients in the general population hospitalized with COVID-19, approximately 20 to 30%
evidence myocardial injury, which is associated with adverse outcomes including cardiac dysfunction,
arrythmia, hypercoagulable events, and death. In addition, significant evidence exists for endothelial and
vascular dysfunction related to COVID-19, related to membrane uptake via ACE-2 or other mechanisms.
People with HIV (PWH) already face increased risk of myocardial infarction and heart failure as compared with
the general population. How COVID-19 affects CV morbidity and mortality among PWH remains unknown and
preventive/therapeutic strategies have yet to be identified. We propose to leverage the REPRIEVE trial – the
largest international randomized trial focused on preventing HIV-associated CV disease – to address critical
knowledge gaps regarding SARS-CoV-2 infection and COVID-related CV complications among PWH. Studying
7,700 PWH ages 40-75 across 5 continents, we will focus on three interrelated but independent key topics:
epidemiology, host factors, and protective strategies. In this regard, statins have pleiotropic effects and
potently reduce vascular inflammation and improve endothelial function, The results of the supplement will
provide critical information on HIV and COVID-19, and conversely critical effects of statins to mitigate effects of
the SARS-Co-V2 virus on cardiovascular disease and endothelial function, and MACE. These results will be
broadly generalizable to the large population of HIV patients simultaneously at risk for COVID-19 and CVD and
also to other populations at risk for CVD experiencing COVID infection.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE Inhibitors><ACE2><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Administrative Supplement><Adrenergic alpha-Antagonists><Adrenergic alpha-Blockers><Adrenergic alpha-Receptor Blockaders><Adrenergic α-Antagonists><Adrenergic α-Blockers><Affect><Age><Aging><Angiotensin I-Converting Enzyme Inhibitors><Angiotensin Receptor><Angiotensin-Converting Enzyme Antagonists><Angiotensin-Converting Enzyme Inhibitors><Anti-Hypertensive Agents><Anti-Hypertensive Drugs><Anti-Hypertensives><Anti-Retroviral Agents><Antibodies><Antihypertensive Agents><Antihypertensive Drugs><Antihypertensives><Antiretroviral Agents><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Blood Cells><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID><COVID disease severity><COVID severity><COVID-19><COVID-19 antibody><COVID-19 disease severity><COVID-19 immunity><COVID-19 infection><COVID-19 severity><COVID-19 virus><COVID19><COVID19 disease severity><COVID19 immunity><COVID19 infection><COVID19 severity><COVID19 virus><CV-19><CV19><Cardiac infarction><Cardiovascular Diseases><Case Series><Cell Count><Cell Number><Cessation of life><Characteristics><CoV disease><CoV-2><CoV2><Cooperative Agreements><Coronary Arteriosclerosis><Coronary Artery Disease><Coronary Artery Disorder><Coronary Atherosclerosis><Death><Diagnosis><Disease><Disease Outcome><Disorder><Drugs><Endothelium><Epidemiology><Ethnic Origin><Ethnicity><Event><Face><Gene variant><General Population><General Public><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic defect><Grant><HIV><HPGF><Heart><Heart failure><Hepatocyte-Stimulating Factor><Hospital Admission><Hospitalization><Host Factor><Host Factor Protein><Human Immunodeficiency Viruses><Hybridoma Growth Factor><Hypercoagulability><Hypotensive Agent><Hypotensive Drugs><Hypotensives><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Immune><Immune Cell Activation><Immunes><Individual><Infection><Inflammatory><Integration Host Factors><Interleukin-6><International><Kaletra><Kininase II Antagonists><Kininase II Inhibitors><Knowledge><LAV-HTLV-III><Lead><Length of Life><Longevity><Lopinavir/Ritonavir><Lymphadenopathy-Associated Virus><MGI-2><Medication><Membrane><Morbidity><Morbidity - disease rate><Mutation><Myeloid Differentiation-Inducing Protein><Myocardial Infarct><Myocardial Infarction><Myocardial depression><Myocardial dysfunction><Myocarditis><NIH><National Institutes of Health><Outcome><Participant><Patients><Pb element><Peripheral Blood Cell><Pharmaceutic Preparations><Pharmaceutical Preparations><Placebos><Plasmacytoma Growth Factor><Population><Populations at Risk><Preventive><Race><Racial Group><Racial Stocks><Randomization trial><Randomized><Risk><SARS><SARS corona virus 2><SARS coronavirus disease><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 disease severity><SARS-CoV-2 immunity><SARS-CoV-2 infection><SARS-CoV-2 severity><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Sham Treatment><Symptoms><T8 Cells><T8 Lymphocytes><Testing><Therapeutic><Thrombophilia><U-Series Cooperative Agreements><United States National Institutes of Health><Vascular Diseases><Vascular Disorder><Virus><Virus-HIV><Wuhan coronavirus><adverse consequence><adverse outcome><ages><allele variant><allelic variant><alpha adrenergic blockade><alpha antiadrenergic agent><alpha blocker><alpha-Adrenergic Blocking Agents><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-retroviral><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody based test><antibody test><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antiretroviral><atherosclerotic coronary disease><blood vessel disorder><cardiac disease risk><cardiac disorder risk><cardiac dysfunction><cardiac failure><cardiac infarct><cardiac inflammation><cardiovascular disorder><cardiovascular endothelium><co-morbid><co-morbidity><comorbidity><corona virus disease><corona virus disease 2019><coronary arterial disease><coronary attack><coronary infarct><coronary infarction><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 disease severity><coronavirus disease 2019 immunity><coronavirus disease 2019 infection><coronavirus disease 2019 severity><coronavirus disease 2019 virus><coronavirus disease severity><drug/agent><endothelial dysfunction><epidemiologic><epidemiological><experience><faces><facial><genetic variant><genome mutation><genomic variant><hCoV19><heart attack><heart disease risk><heart disorder risk><heart dysfunction><heart infarct><heart infarction><heavy metal Pb><heavy metal lead><immune activation><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><injury to the myocardium><interest><interferon beta 2><life span><lifespan><membrane structure><mortality><myocardial injury><nCoV2><parent grant><pleiotropic effect><pleiotropism><pleiotropy><prevent><preventing><randomisation><randomization><randomized trial><randomly assigned><response><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 severity><sex><sham therapy><uptake><vascular dysfunction><vascular inflammation><vasculopathy><α blocker>